Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7P16 (ribosomal protein L7 pseudogene 16) is a processed pseudogene derived from the RPL7 gene, which encodes the 60S ribosomal protein L7, a component of the large subunit of the eukaryotic ribosome[5]. Pseudogenes like RPL7P16 are genetic sequences that resemble functional genes but typically lack coding potential due to disabling mutations or sequence interruptions. While the parental RPL7 protein plays a role in ribosomal structure and cellular protein synthesis, RPL7P16 does not produce a functional protein and has no known biological activity or therapeutic relevance. Such pseudogenes are common in the genome and are generally considered nonfunctional "genetic fossils," though in rare cases other pseudogenes can contribute regulatory RNAs, this is not documented for RPL7P16[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 16 (RPL7P16).